Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - Seite 2

At December 31, 2023, the Company had positive working capital of approximately $477,881.

For the three and twelve months ending December 31, 2023 the Company reported a net loss of $722,733 and $2,612,925, respectively. Research and development operating expenses were $419,482 and $1,671,677 for the three and twelve months ended December 31, 2023, respectively. General and administrative expenses were $241,928 and $810,424 for the three and twelve months ending December 31, 2023, respectively. Total cash operating expenses related to research and development and general and administrative expenses for the three and twelve months ended December 31, 2022 were $488,414 and $1,816,715, respectively.

Selected Financial Information	As at December 31, 2023 $
Cash & cash equivalents	436,313
Working capital	477,881
Intangible assets	4,515,051
Total Assets	5,147,579
Total liabilities	1,487,743
Deficit	(10,925,311	)
Total equity	3,659,836

Statements of net loss and comprehensive loss data:	For the three months ended December 31, 2023 $		For the year ended December 31, 2023 $
Research & Development	419,482		1,671,677
General and administrative	241,928		810,424
Net loss and comprehensive loss	(722,733	)	(2,612,925	)
Basic and diluted income (loss) per share	(0.01	)	(0.04	)
Operating cash burn	488,414		1,816,715
Weighted average shares outstanding	69,904,462		69,848,394

Rakovina Therapeutics’ financial statements as filed with SEDAR can be accessed from the Company’s website at: https://www.rakovinatherapeutics.com/corporate-profile/